newsfilter
← Latest News
ACCESS Newswire·

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

  • IGC Pharma, Inc. (NYSE: IGC) received U.S. Patent No. 12,465,589 from the USPTO on November 11, 2025, for methods & compositions to treat CNS disorders.
  • The patent covers the proprietary formulation used in IGC-AD1, the company's lead drug candidate currently in the Phase 2 CALMA trial for agitation in Alzheimer's disease.
  • The granted composition targets Alzheimer's disease mechanisms including amyloid plaques, tau tangles, & symptoms such as agitation, memory loss, cognition issues, anxiety, & sleep disturbances.
  • The patented approach aims to reduce amyloid-beta expression & aggregation, enhance mitochondrial function, decrease GSK3β phosphorylation, & lower tau phosphorylation.
  • IGC Pharma states the combination is designed to address behavioral symptoms & core disease mechanisms without serious side effects.
  • The company continues to research pathways underlying Alzheimer's progression, including Aβ aggregation, tau pathology, mitochondrial dysfunction, & neuroinflammation.
  • IGC Pharma is a clinical-stage biotechnology firm leveraging AI to develop treatments for Alzheimer's & metabolic disorders, with additional pipeline assets including TGR-63.
  • The press release includes standard forward-looking statements warnings regarding risks such as regulatory approval, AI algorithm performance, & economic conditions.